Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Altshuler Shaham Ltd

Altshuler Shaham Ltd cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 37.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,739 shares of the company’s stock after selling 51,609 shares during the quarter. Altshuler Shaham Ltd’s holdings in Takeda Pharmaceutical were worth $1,209,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. XY Capital Ltd boosted its stake in Takeda Pharmaceutical by 432.5% in the 4th quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock worth $10,919,000 after purchasing an additional 621,440 shares during the period. FMR LLC lifted its stake in Takeda Pharmaceutical by 4.7% in the 3rd quarter. FMR LLC now owns 2,593,350 shares of the company’s stock worth $40,119,000 after acquiring an additional 115,947 shares in the last quarter. Brandes Investment Partners LP boosted its position in Takeda Pharmaceutical by 2.1% during the 3rd quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after acquiring an additional 36,717 shares during the period. Citigroup Inc. grew its stake in Takeda Pharmaceutical by 5.6% during the 3rd quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock valued at $896,000 after acquiring an additional 3,089 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical in the third quarter worth approximately $2,105,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 2.5 %

TAK traded up $0.32 on Thursday, reaching $13.38. 2,941,880 shares of the company traded hands, compared to its average volume of 1,792,912. The stock’s 50 day moving average price is $13.82 and its 200-day moving average price is $14.09. The company has a market cap of $42.35 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 3.05 and a beta of 0.56. Takeda Pharmaceutical Company Limited has a 52-week low of $12.77 and a 52-week high of $17.03. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.